ARS Pharmaceuticals, Inc. (SPRY)
NASDAQ: SPRY · Real-Time Price · USD
4.070
-0.050 (-1.21%)
At close: Oct 2, 2026, 4:00 PM EDT
4.150
+0.080 (1.97%)
After-hours: Oct 2, 2026, 7:44 PM EDT
ARS Pharmaceuticals Employees
As of June 30, 2026, ARS Pharmaceuticals had 200 total employees, including 195 full-time and 5 part-time employees. The number of employees increased by 33 or 19.76% compared to the same quarter last year.
Employees
200
Change
33
Growth
19.76%
Revenue / Employee
$584,635
Profits / Employee
-$1,077,160
Market Cap
404.75M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2026 | 200 | 33 | 19.76% | 195 | 5 |
| Mar 31, 2026 | 159 | -1 | -0.63% | 154 | 5 |
| Dec 31, 2025 | 163 | 3 | 1.88% | 158 | 5 |
| Sep 30, 2025 | 167 | 16 | 10.60% | 162 | 5 |
| Jun 30, 2025 | 167 | 139 | 496.43% | 162 | 5 |
| Dec 31, 2024 | 160 | 134 | 515.38% | 155 | 5 |
| Sep 30, 2024 | 151 | 124 | 459.26% | 146 | 5 |
| Jun 30, 2024 | 28 | -6 | -17.65% | 23 | 5 |
| Mar 31, 2024 | 26 | -5 | -16.13% | 24 | 2 |
| Dec 31, 2023 | 26 | 6 | 30.00% | 24 | 2 |
| Sep 30, 2023 | 27 | 16 | 145.45% | 24 | 3 |
| Jun 30, 2023 | 34 | 23 | 209.09% | 29 | 5 |
| Mar 31, 2023 | 31 | 22 | 244.44% | 27 | 4 |
| Dec 31, 2022 | 20 | 11 | 122.22% | 17 | 3 |
| Jun 30, 2022 | 11 | - | - | 9 | 2 |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Kyverna Therapeutics | 149 |
| C4 Therapeutics | 104 |
| Agenus | 81 |
| Prelude Therapeutics | 79 |
| Rezolute | 68 |
| Prothena Corporation | 67 |
| Tectonic Therapeutic | 60 |
| Atea Pharmaceuticals | 55 |
SPRY News
- 10 days ago - Kaplan Fox Reminds ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors with Significant Losses to Seek a Leadership Role Before Deadline on October 5, 2026 - GlobeNewsWire
- 11 days ago - Kaplan Fox Encourages Investors of ARS Pharmaceuticals Inc. (SPRY) to Act Ahead of the Lead Plaintiff Deadline on October 5, 2026 - Newsfile Corp
- 15 days ago - Kaplan Fox Alerts ARS Pharmaceuticals Inc. (SPRY) Investors to the Lead Plaintiff Deadline on October 5, 2026 - Newsfile Corp
- 17 days ago - Kaplan Fox Urges ARS Pharmaceuticals Inc. (SPRY) Investors Seeking Recovery to Contact the Firm Before October 5, 2026 - Newsfile Corp
- 22 days ago - ARS Pharmaceuticals Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 25 days ago - Kaplan Fox Encourages ARS Pharmaceuticals Inc. (SPRY) Investors to Contact the Firm Before the Lead Plaintiff Deadline on October 5, 2026 - Newsfile Corp
- 25 days ago - ARS Pharmaceuticals price target lowered to $15 from $18 at Leerink - TheFly
- 4 weeks ago - ARS Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewsWire